Can Align Technology (ALGN) Still Be Undervalued After Its Review?
Align Technology, Inc. ALGN | 0.00 |
Align Technology stock sits at an interesting point for valuation minded investors. The share price has recovered strongly over the past year, yet a Discounted Cash Flow (DCF) intrinsic value estimate still points to a sizeable gap to the current market price.
- Over the last 5 years Align Technology shares have declined about 74%, which means the recent rebound comes after a long period of weak returns for long term holders.
- New digital tools showcased at the 2026 Invisalign Ortho Summit can support expectations for future cash flows, while execution risks around the broader operating model review and any changes it brings may affect how reliably those cash flows are delivered.
- The stock scores 3 out of 6 on valuation checks, which points to a mixed picture rather than a clear bargain or clear overvaluation.
The issue now is whether Align Technology's current price already reflects its long term potential or if the DCF implied undervaluation still leaves room for upside.
Is Align Technology Still Cheap on Cash Flow?
The Discounted Cash Flow (DCF) approach used here values Align Technology based on the cash it is expected to generate for shareholders. The model uses last twelve month free cash flow of about $568 million and assumes cash flows continue to grow from this base. On that basis, it arrives at an estimated intrinsic value of about $298.59 per share.
Compared with the current share price, that DCF estimate implies the stock trades at roughly a 39.7% discount, so Align Technology screens as undervalued on this cash flow view. The recent operating model review and new digital tools showcased at the 2026 Invisalign Ortho Summit help explain why expectations for future cash flows sit at healthy levels, even if execution remains a key watchpoint.
Overall, the DCF analysis indicates that Align Technology stock currently appears undervalued relative to the cash flows implied in this model.
Our Discounted Cash Flow (DCF) analysis suggests Align Technology is undervalued by 39.7%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.
Where Does Align Technology Sit on Earnings?
The P/E multiple is a useful way to look at Align Technology because earnings are a key focus for many investors in the medical equipment sector. Align Technology currently trades on a P/E of about 30.0x, which sits slightly above the medical equipment industry average of around 29.3x and just under the peer group average near 32.3x.
The model based fair P/E ratio for Align Technology is about 27.9x, which is only modestly below the current 30.0x. This suggests the market price is broadly in line with what might be expected given the company’s profile, rather than signaling a sharp premium or discount to peers.
On balance, Align Technology stock appears roughly fairly valued on its current P/E multiple.
The Align Technology Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Align Technology pick up where the P/E and DCF checks leave off and explain which assumptions about Align Technology's future margins, growth and earnings would need to hold for the stock to be worth materially more or less than today's price. Each Narrative treats fair value as a thesis about how the business might evolve that you can track over time, and these sit on Simply Wall St's Community page.
Community views on Align Technology sit far apart, with one side focused on platform upside and the other on pricing and demand pressure.
Bull case: 14% undervalued
"Bullish analysts point to multiple platform growth levers, including teen conversion, Advanced Restorative Treatment with lab partnerships, peer to peer channel expansion, continued ClinCheck development, and plans to scale direct fabrication, as key supports for revenue and margin potential over time..."
Bear case: 16% overvalued
"Today, Align operates in a different environment. Inflation, discretionary spending pressure, and rising competition are testing whether premium orthodontics can sustain growth without sacrificing margins..."
Do you think there's more to the story for Align Technology? Head over to our Community to see what others are saying!
The Bottom Line
For Align Technology, the Discounted Cash Flow (DCF) intrinsic value estimate still points to meaningful undervaluation, while the P/E view suggests the stock is priced roughly in line with peers. That mixed signal fits with the broader valuation checks and keeps the focus on execution rather than a clear-cut bargain. The key question from here is whether Align Technology can convert its product roadmap and operating model changes into durable cash flows without eroding margins. If that occurs, the current discount could be attractive, but if execution stumbles, the gap may simply reflect the risk the market is already pricing in.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
